This Viewpoint summarizes recommendations made in a 2017 Blueprint for Transparency at the US Food and Drug Administration developed to encourage increased public access to FDA analyses and regulatory decisions.
No takes yet. Share an insight, caveat, or question.
Sharfstein et al. (2017) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: